- Home
- PAYS vs FATE Comparison
PAYS vs FATE Comparison
Compare PAYS & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- FATE
- Stock Information
- Founded
- PAYS 2001
- FATE 2007
- Country
- PAYS United States
- FATE United States
- Employees
- PAYS N/A
- FATE N/A
- Industry
- PAYS Business Services
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAYS Consumer Discretionary
- FATE Health Care
- Exchange
- PAYS Nasdaq
- FATE Nasdaq
- Market Cap
- PAYS 125.2M
- FATE 130.7M
- IPO Year
- PAYS 1998
- FATE 2013
- Fundamental
- Price
- PAYS $5.82
- FATE $1.01
- Analyst Decision
- PAYS Strong Buy
- FATE Hold
- Analyst Count
- PAYS 4
- FATE 7
- Target Price
- PAYS $7.31
- FATE $3.83
- AVG Volume (30 Days)
- PAYS 1.0M
- FATE 1.3M
- Earning Date
- PAYS 08-05-2025
- FATE 08-12-2025
- Dividend Yield
- PAYS N/A
- FATE N/A
- EPS Growth
- PAYS N/A
- FATE N/A
- EPS
- PAYS 0.12
- FATE N/A
- Revenue
- PAYS $68,539,381.00
- FATE $13,335,000.00
- Revenue This Year
- PAYS $31.28
- FATE N/A
- Revenue Next Year
- PAYS $19.36
- FATE N/A
- P/E Ratio
- PAYS $43.51
- FATE N/A
- Revenue Growth
- PAYS 27.84
- FATE 105.85
- 52 Week Low
- PAYS $1.80
- FATE $0.66
- 52 Week High
- PAYS $8.88
- FATE $4.61
- Technical
- Relative Strength Index (RSI)
- PAYS 33.51
- FATE 38.59
- Support Level
- PAYS $5.09
- FATE $1.02
- Resistance Level
- PAYS $7.28
- FATE $1.13
- Average True Range (ATR)
- PAYS 0.53
- FATE 0.08
- MACD
- PAYS -0.37
- FATE -0.02
- Stochastic Oscillator
- PAYS 15.19
- FATE 4.24
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.